Systematic review/Meta analysis 12 February 2026

DYSF gene variant spectrum in Arab populations across eight countries: A systematic review

Authors

CC BY 4.0 Published: 12 February 2026 DOI: 10.17305/bb.2026.13439

Abstract

Dysferlinopathies are a subset of autosomal recessive muscular dystrophies resulting from pathogenic variants in the dysferlin (DYSF) gene. The prevalence of dysferlinopathies remains inadequately defined. This review aims to elucidate the mutational spectrum of DYSF in Arab populations. A systematic search was conducted in PubMed, ScienceDirect, Scopus, and Web of Science up to September 15, 2025. We identified 48 unique DYSF variants documented in the literature across eight Arab countries, resulting in 49 country-entries due to one variant being reported in two countries. The distribution of reported variants was as follows: Saudi Arabia 32.7% (16/49), Algeria 20.4% (10/49), Egypt 20.4% (10/49), Tunisia 10.2% (5/49), Morocco 6.1% (3/49), Libya 4.1% (2/49), Lebanon 4.1% (2/49), and Oman 2.0% (1/49). Clinical presentations were categorized based on phenotype assignments across variants, totaling 52 assignments as some variants were associated with multiple phenotypes: limb-girdle muscular dystrophy, recessive type 2 (LGMDR2) 50% (26/52), proximodistal 15% (8/52), Miyoshi myopathy 8% (4/52), distal myopathy with anterior tibial onset (DMAT) 4% (2/52), and asymptomatic hyperCKemia 4% (2/52). In terms of molecular consequences (denominator = 48 unique variants), frameshift variants constituted 36% (17/48), missense variants 29% (14/48), nonsense variants 15% (7/48), splice donor variants 6% (3/48), splice acceptor variants 4% (2/48), intronic variants 2% (1/48), and synonymous variants 2% (1/48). Documenting these variants across populations facilitates diagnosis and informs future public health strategies. Notably, no cohort study based in Morocco has focused on the genetics of dysferlinopathy; existing Moroccan data are limited to isolated case reports.

Keywords

Dysferlinopathy DYSF mutations Arab populations

Full text

Introduction

Dystrophy-associated fer-1-like protein, commonly referred to as human dysferlin, is a large transmembrane protein with a molecular weight of 238 kDa that belongs to the Ferlin protein family [1–10]. Dysferlin plays a crucial role in calcium signaling, sarcomere stability, membrane fusion, and repair [11–14].

The amino acid sequence of dysferlin is similar to that of the fer-1 protein found in the nematode Caenorhabditis elegans [3, 15–19].

The gene symbol for dysferlin is DYSF, as indicated in the Online Mendelian Inheritance in Man (OMIM) database under entry 603009. This extensive gene is located on chromosome 2 (p13.3) and spans over 150 kb of genomic DNA, with coding regions constituting only 1.67% distributed across 55 exons [1, 20, 21].

Dysferlinopathies represent a group of rare autosomal recessive muscular dystrophies caused by pathogenic variants in the DYSF gene, characterized by a heterogeneous spectrum of muscle disorders. Currently, the clinical presentations of Miyoshi Myopathy and limb-girdle muscular dystrophy (LGMD) type R2 are considered manifestations of the same condition, as the same mutation can lead to both clinical presentations. Additional minor symptoms associated with dysferlinopathy include asymptomatic hyperCKemia, distal myopathy with anterior tibial onset (DMAT), proximodistal (PD) myopathy, and pseudometabolic myopathy [22–24].

Since the identification of the first mutation in the DYSF gene in 1998 [25], a total of 909 pathogenic or likely pathogenic variants have been reported in the ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/, last accessed on January 7, 2026), with over 700 variants documented in the Leiden Open Variation Database (LOVD: https://databases.lovd.nl/shared/genes/DYSF). Establishing a genotype-phenotype correlation is challenging due to the diverse clinical phenotypes observed in dysferlinopathy patients [26–28].

A regional approach to identifying genetic mutations in the DYSF gene within the Arab population is essential. Disparities in diagnosis in these populations, particularly due to unequal access to molecular diagnostic tools, may result in significant underestimation of the true prevalence of dysferlinopathies. Additionally, the high frequency of consanguinity in certain countries contributes to the presence of founder mutations. Identifying these recurrent mutations enhances the accuracy of genetic diagnoses, facilitates targeted screening strategies, and optimizes genetic counseling and family care [29–33].

The objective of this review is to highlight the mutational spectrum of the DYSF gene in the Arab world, particularly in Morocco, based on literature data and our hospital database of patients affected by dysferlinopathy.

Materials and methods

Search strategy

The literature search was conducted using the PubMed, ScienceDirect, Scopus, and Web of Science databases. Our research utilized the following keywords: “Dysferlinopathy” OR “Dysferlinopathie” AND “DYSF gene mutation in Morocco” OR “DYSF gene mutation in Tunisia” OR “DYSF gene mutation in Algeria” OR “DYSF gene mutation in Saudi Arabia” OR “DYSF gene mutation in Lebanon” OR “DYSF gene mutation in Libya” OR “DYSF gene mutation in Egypt” OR “DYSF gene mutation in Oman” OR “DYSF gene mutation in Mauritania” OR “DYSF gene mutation in Sudan” OR “DYSF gene mutation in Djibouti” OR “DYSF gene mutation in Somalia” OR “DYSF gene mutation in Yemen” OR “DYSF gene mutation in United Arab Emirates” OR “DYSF gene mutation in Qatar” OR “DYSF gene mutation in Bahrain” OR “DYSF gene mutation in Kuwait” OR “DYSF gene mutation in Iraq” OR “DYSF gene mutation in Syria” OR “DYSF gene mutation in Jordan” OR “DYSF gene mutation in Palestine” OR “DYSF gene mutation in Comoros” AND “Dysferlin” AND “Ferlin protein” OR “Ferlin” AND “Arab populations” AND “DYSF” OR “DYSF gene mutation c.5594delG” OR “c.5594delG”.

A total of 252 potentially relevant records in English and French were identified through database searches and citation screening. After removing 150 duplicates, 102 records remained for title and abstract screening, leading to the exclusion of 52 articles that did not align with the review objectives. The full texts of the remaining 50 articles were independently assessed by three reviewers, resulting in the exclusion of 35 studies. Ultimately, 15 studies met the inclusion criteria and were incorporated into the review (Figure 1).

Figure 1.
Figure 1. PRISMA diagram illustrating the process of research selection and study inclusion [34].

The literature search was not limited to full-length peer-reviewed articles; it also included published abstracts. The search encompassed literature from 1980 through September 15, 2025.

Eligibility criteria

Studies included in this review were those reporting clinical and genetic data from patients diagnosed with dysferlinopathy in Arab populations, with documented variants in the DYSF gene. Publications describing the molecular structure and functional characteristics of the dysferlin protein, as well as cohort studies involving patients affected by dysferlinopathy, were also included. Variant information was gathered from relevant curated genetic databases, including LOVD and ClinVar.

Exclusion criteria encompassed publications that did not report pathogenic or likely pathogenic variants in the DYSF gene in individuals from Arab populations, studies focusing on myopathies unrelated to dysferlinopathy, research conducted in non-Arab populations, and publications lacking detailed molecular characterization of DYSF gene variants.

Two reviewers independently performed study selection based on predefined inclusion and exclusion criteria. Disagreements were resolved by consensus or, when necessary, through consultation with a third reviewer. The details of the data extraction are presented in Table S1.

Risk of bias assessment

This systematic review adhered to a predefined protocol in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [34]. To evaluate the potential risk of bias in the included studies, reviewers assessed methodological quality using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports and Case Series [35–37]. The JBI checklist comprises 10 items for case series and 8 items for case reports, with results displayed in Tables S2 and S3.

Procedure for counting identified mutations

The analysis of mutations was based on the various variants reported by country.

We identified a total of 48 distinct mutations across 8 countries. Compound heterozygous mutations were considered separately, eliminating duplicates. The analysis and interpretation of data to determine molecular consequences, clinical classification, and information from the LOVD and ClinVar databases followed the same principles.

The classification of the reported variants was based on published data, supplemented by direct consultation of the LOVD and ClinVar databases, which were last accessed on January 7, 2026.

This study aimed to conduct a targeted and detailed investigation of the various mutations of the DYSF gene in the Arab world as reported in the literature. During our research, we formulated several questions that guided our exploration:

  • What are the different mutations of the DYSF gene described in scientific publications that have been identified in Arab patients?
  • Are there similarities among Arab countries regarding the published mutations of the DYSF gene?

In Morocco:

  • What mutations have been identified in the DYSF gene?
  • In how many patients has a mutation in the DYSF gene been identified?
  • How many references to the DYSF gene have been cited in Morocco?
  • Is there a founder effect associated with a mutation in the DYSF gene in the Moroccan population?

Results

According to our literature review, forty-eight mutations in the DYSF gene have been reported in Arab populations. All analyses pertaining to molecular consequences and results from LOVD/ClinVar were performed using 48 as the denominator (unique variants), while analyses related to clinical classification, phenotype, and geographical origin were based on 49 entries (as one mutation occurs in two countries). The denominator for clinical presentations is 52, as some mutations are associated with multiple phenotypes. Fifteen publications [19, 29–31, 38–48] have described mutations of the DYSF gene in Saudi Arabia, Egypt, Algeria, Tunisia, Morocco, Libya, Lebanon, and Oman. To date, there are no reports of mutations in the DYSF gene for other countries, including Mauritania, Sudan, Djibouti, Somalia, Yemen, United Arab Emirates, Qatar, Bahrain, Kuwait, Iraq, Syria, Jordan, Palestine, and Comoros.

Sixteen mutations have been reported in Saudi Arabia, including 11 substitutions: c.89-1G>A; c.359A>C (p.Gln120Pro); c.631A>G (p.Lys211Glu); c.755C>T (p.Thr252Met); c.1351A>G (p.Met451Val); c.1422C>T; c.3702+6T>A; c.4873C>T (p.Arg1625*); c.5201A>T (p.Tyr1734Phe); c.5264T>C (p.Leu1755Pro); and c.5907G>C (p.Trp1969Cys). Additionally, there are two duplications: c.164dupA (p.Ile57Hisfs8) and c.166dupA (p.L55fs); two insertions: c.164_165insA and c.4210_4211insC (p.Lys1404Thrfs5); and one deletion: c.1433delC (Table 1, Table S4, and Figure 2).

Table 1 Summary of DYSF gene mutation data reported in arab populations from published studies
Mutations Protein change Exon Molecular consequence Zygosity Clinical classification Phenotype LOVD ClinVar Geographical origin Number of patients Reference
c.89-1G>A NR 2 Splice acceptor Homozygous Pathogenic LGMDR2 √ √ Saudi Arabia 1 (1 family) [31]
c.164dupA p.Ile57Hisfs*8 3 Frameshift Homozygous Pathogenic LGMDR2 √ √ Saudi Arabia 1 (1 family) [42]
c.631A>G p.Lys211Glu 6 Missense Homozygous Pathogenic LGMDR2 NR √ Saudi Arabia 1 (1 family) [31]
c.164_165insA NR 3 Frameshift Homozygous Pathogenic LGMDR2 NR NR Saudi Arabia 28 (19 families) [31]
c.166dupA p.L55fs 3 Frameshift Homozygous Pathogenic LGMDR2 NR NR Saudi Arabia 1 (1 family) [41]
c.1351A>G p.Met451Val 14 Missense Compound heterozygous VUS LGMDR2 √ √ Saudi Arabia 1 (1 family) [31]
c.5264T>C p.Leu1755Pro 38 Missense NR NR NR Saudi Arabia
c.3702+6T>A NR 2 Intronic NR NR √ Saudi Arabia
c.1422C>T NR 16 Silent Compound heterozygous Likely pathogenic LGMDR2 NR NR Saudi Arabia 1 (1 family) [31]
c.359A>C p.Gln120Pro 16 Missense Likely pathogenic NR √
c.1433delC NR 16 Frameshift Homozygous Pathogenic LGMDR2 NR NR Saudi Arabia 3 (2 families) [31]
c.4210_4211insC p.Lys1404Thrfs*5 39 Frameshift Homozygous Pathogenic LGMDR2 NR NR Saudi Arabia 1 (1 family) [31]
c.4873C>T p.Arg1625* NR Nonsense Homozygous Pathogenic LGMDR2 NR √ Saudi Arabia NR [43]
c.5201A>T p.Tyr1734Phe 46 Missense Homozygous NR LGMDR2 NR √ Saudi Arabia 1 (1 family) [31]
c.5907G>C p.Trp1969Cys 52 Missense Homozygous VUS LGMDR2 √ √ Saudi Arabia 1 (1 family) [31]
c.755C>T p.Thr252Met 7 Missense Homozygous VUS LGMDR2 √ √ Saudi Arabia 1 (1 family) [31]
c.342+1G>A NR Intron 4 Splice donor Homozygous Pathogenic NR √ √ Egypt [45]
c.755C>T p.Thr252Met 7 Missense Homozygous Pathogenic NR √ √ Egypt [45]
c.1958delG p.Gly653Valfs*3 21 Frameshift Homozygous Pathogenic NR √ NR Egypt [45]
c.2190dupA p.Pro731Thrfs*23 NR NR Compound heterozygous NR NR NR NR Egypt 21 patients [45]
c.3597G>A p.Trp1199* 33 Nonsense Pathogenic NR √ √ Egypt
c.3944_3948delinsG p.Glu1315Glyfs*29 NR NR NR NR NR NR NR Egypt [45]
c.4101G>A NR NR NR Compound heterozygous NR NR NR NR Egypt [45]
c.6124C>T p.Arg2042Cys 54 Missense Pathogenic NR √ NR Egypt
c.4431G>T p.Trp1477Cys NR Missense Homozygous Pathogenic NR √ NR Egypt [45, 46]
c.5983_5984del p.Ser1995* NR Frameshift Homozygous NR NR NR NR Egypt [45]
c.457+2T>G p.Ala115_Asp153 Intron 5 Splice donor Homozygous Pathogenic LGMDR2 √ √ Algeria 1 (1 family) [38]
c.1663C>T p.Arg555Trp 19 Missense Homozygous Pathogenic MM √ √ Algeria 1 (1 family) [38]
c.1795_1799dup p.Ala601Thrfs*28 20 Frameshift Homozygous Pathogenic MM √ NR Algeria 2 (1 family) [38]
c.1834C>T p.Gln612* 20 Nonsense Compound heterozygous Pathogenic LGMDR2 √ √ Algeria [38]
c.3967C>T p.Gln1323* 37 Nonsense Pathogenic √ NR Algeria 2 (1 family)
c.1834C>T p.Gln612* 20 Nonsense Pathogenic PD phenotype √ √ Algeria
c.4876delG p.Val1626Tyrfs*8 44 Frameshift Compound heterozygous Pathogenic √ NR Algeria
c.2643+1G>A p.Tyr838_Thr881del Intron 25 Splice donor Homozygous Pathogenic LGMDR2 √ √ Algeria 2 (1 family) [40]
c.3035G>A p.Trp1012* 29 Nonsense Homozygous Pathogenic LGMDR2 √ √ Algeria 2 (1 family) [38]
c.4201dupA p.Ile1401Asnfs*8 39 Frameshift Homozygous Pathogenic PD phenotype √ NR Algeria 1 (1 family) [38]
c.5296G>T p.Glu1766* 47 Nonsense Homozygous Pathogenic PD phenotype √ √ Algeria 1 (1 family) [38]
c.1392dupA p.Asp465Argfs*9 15 Frameshift Homozygous Pathogenic -DMAT -PD phenotype √ √ Tunisia 4 (2 families:3/1) [29, 38]
c.3113G>A p. Arg1038Gln 29 Missense Homozygous Likely pathogenic -HyperCKemia -LGMDR2 -PD phenotype √ √ Tunisia 9 (3 families: 6/2/1) [29]
c.4200dupC p.Ile1401Hisfs*8 39 Frameshift Homozygous Pathogenic -LGMDR2 -MM -HyperCKemia √ √ Tunisia 4 (2 families: 1/3) [29]
c.4597-2A>G NR 43 Splice acceptor Homozygous Pathogenic -DMAT -PD phenotype -LGMDR2 NR NR Tunisia 3 (1 family) [29, 39]
c.5525G>A p.Gly1842Asp 49 Missense Homozygous Pathogenic PD phenotype √ NR Tunisia 1 (1 family) [29]
c.2858dupT p.Phe954Valfs*2 27 Frameshift Homozygous Pathogenic LGMDR2 √ √ Morocco 1 (1 family) [38, 47]
c.4200delC p.Ile1401Serfs*47 39 Frameshift Homozygous Pathogenic LGMDR2 √ √ Morocco 1 (1 family) [38]
c.5594delG p.Gly1865Alafs*101 50 Frameshift Homozygous Pathogenic PD phenotype √ √ Morocco 1 (1 family) [38, 47]
c.4872delG p.Glu1624Aspfs*10 44 Frameshift Homozygous Pathogenic LGMDR2 √ √ Libya 29 (12 families) [30]
c.5434ins (5410–5433 tandem repeat at 5434) NR 46 Frameshift Homozygous Pathogenic LGMDR2 NR NR Libya NR [19]
c.5438T>C p.Leu1813Pro 49 Missense Homozygous Pathogenic LGMDR2 √ NR Lebanon 2 (2 families) [44]
c.5555T>C p.Lys1852Pro 50 Missense Homozygous Likely pathogenic LGMDR2 NR √ Lebanon NR [43]
c.526C>T p.Gln176* 6 Nonsense Homozygous Pathogenic MM √ √ Oman NR [48]

Variant nomenclature was verified using several databases, including LOVD, ClinVar, VariantValidator (https://variantvalidator.org/), VarSome (https://varsome.com/), and Mutalyzer (https://mutalyzer.nl), all accessed on January 7, 2026. Abbreviations: LGMDR2: Limb-girdle muscular dystrophy, recessive type 2; MM: Miyoshi myopathy; DMAT: Distal myopathy with anterior tibial onset; PD: Proximodistal; VUS: Variant of uncertain significance; √: Found; NR: Not reported.

Figure 2.
Figure 2. Geographical distribution of reported DYSF variants in Arab countries. Arab countries are shaded in purple; the eight countries with published DYSF variants included in this review are numbered as follows: 1 Morocco, 2 Algeria, 3 Tunisia, 4 Libya, 5 Egypt, 6 Lebanon, 7 Saudi Arabia, and 8 Oman. For each numbered country, the corresponding box lists the DYSF variants reported in the literature, presented using HGVS cDNA nomenclature (prefix “c.”). Overall, 48 unique variants were identified across these eight countries, yielding 49 country-entries because the c.755C>T variant was reported in both Saudi Arabia and Egypt; no published DYSF variants were identified for other Arab countries within the search timeframe (through 15 September 2025). Abbreviations: cDNA: Complementary DNA; DYSF: Dysferlin; HGVS: Human Genome Variation Society.

In Egypt, ten mutations have been reported, comprising six substitutions: c.342+1G>A; c.755C>T (p.Thr252Met); c.3597G>A (p.Trp1199*); c.4101G>A; c.4431G>T (p.Trp1477Cys); and c.6124C>T (p.Arg2042Cys). There are also two deletions: c.1958delG (p.Gly653Valfs3) and c.5983_5984del (p.Ser1995); one duplication: c.2190dupA (p.Pro731Thrfs23); and one deletion-insertion mutation: c.3944_3948delinsG (p.Glu1315Glyfs29) (Table 1, Table S4, and Figure 2).

Algeria has identified ten different mutations in the DYSF gene, including seven substitutions: c.457+2T>G (p.Ala115_Asp153); c.1663C>T (p.Arg555Trp); c.1834C>T (p.Gln612*); c.2643+1G>A (p.Tyr838_Thr881del); c.3035G>A (p.Trp1012*); c.3967C>T (p.Gln1323*); and c.5296G>T (p.Glu1766*). Additionally, there are two duplications: c.1795_1799dup (p.Ala601Thrfs28) and c.4201dupA (p.Ile1401Asnfs8); and one deletion: c.4876delG (p.Val1626Tyrfs*8) (Table 1, Table S4, and Figure 2).

In Tunisia, five different mutations in the DYSF gene have been reported, consisting of three substitutions: c.3113G>A (p.Arg1038Gln); c.4597-2A>G; and c.5525G>A (p.Gly1842Asp) along with two duplications: c.1392dupA (p.Asp465Argfs9) and c.4200dupC (p.Ile1401Hisfs8) (Table 1, Table S4, and Figure 2).

Morocco has identified three mutations: two deletions, c.5594delG (p.Gly1865Alafs101) and c.4200delC (p.Ile1401Serfs47), and one duplication, c.2858dupT (p.Phe954Valfs*2) (Table 1, Table S4, and Figure 2).

In the Lebanese population, two substitutions have been reported: c.5438T>C (p.Leu1813Pro) and c.5555T>C (p.Lys1852Pro) (Table 1, Table S4, and Figure 2).

Libya has reported two mutations: one deletion, c.4872delG (p.Glu1624Aspfs*10), and one insertion, c.5434ins (5410_5433 tandem repeat at 5434) (Table 1, Table S4, and Figure 2).

In Oman, one nonsense mutation has been described: c.526C>T (p.Gln176*) (Table 1, Table S4, and Figure 2).

This review indicates that Saudi Arabia has the highest percentage of reported DYSF mutations (32.7%), followed by Algeria (20.4%), Egypt (20.4%), Tunisia (10.2%), Morocco (6.1%), Lebanon (4.1%), Libya (4.1%), and Oman (2%) (Figure 3).

Figure 3.
Figure 3. Distribution of reported DYSF variants across Arab countries. Blue bars indicate the number of reported DYSF variant country-entries per country, and orange bars indicate the corresponding percentage of all country-entries identified in this review (total = 49). Percentages were calculated using country-entries rather than unique variants because one variant (c.755C>T) was reported in both Saudi Arabia and Egypt. Saudi Arabia contributed the highest proportion (16/49, 32.7%), followed by Egypt and Algeria (10/49 each, 20.4%), Tunisia (5/49, 10.2%), Morocco (3/49, 6.1%), Lebanon and Libya (2/49 each, 4.1%), and Oman (1/49, 2.0%). Abbreviation: DYSF: Dysferlin.

Only one variant overlap was observed among the studied countries, specifically c.755C>T, identified in both Saudi Arabia and Egypt. All other variants were unique to their respective countries.

The most prevalent clinical presentation of dysferlinopathy in our study is LGMD type 2 (LGMDR2) (50%), followed by the PD phenotype (15%), miyoshi myopathy (MM) (8%), DMAT (4%), and asymptomatic hyperCKemia (4%). The specific type of dysferlinopathy remained unknown for 19% of the reported mutations (Figure 4).

Figure 4.
Figure 4. Clinical presentation distribution across reported DYSF variant phenotype assignments in Arab populations. Blue bars indicate the number of phenotype assignments (“reports”) and orange bars indicate the corresponding percentage of all phenotype assignments identified in this review (total = 52); percentages sum to 100% because some variants were associated with more than one clinical presentation. LGMDR2 was the most frequent presentation (26/52, 50%), followed by PD phenotype (8/52, 15%), MM (4/52, 8%), DMAT (2/52, 4%), and hyperCKemia (2/52, 4%). In 10/52 assignments (19%), the clinical presentation was not specified in the source report (Unknown). Abbreviations: DYSF: Dysferlin; DMAT: Distal myopathy with anterior tibial onset; LGMDR2: Limb-girdle muscular dystrophy, recessive type 2; MM: Miyoshi myopathy; PD: Proximodistal; hyperCKemia: Hypercreatine kinaseemia.

The distribution of disease-causing mutations identified in the literature among patients of Arab origin is as follows: 36% frameshift, 29% missense, 15% nonsense, 6% splice donor, and 4% splice acceptor mutations. Intronic and silent mutations account for 2% each, while 6% of mutations were unreported (Figure 5).

Figure 5.
Figure 5. Distribution of reported DYSF variants by predicted molecular consequence. Blue bars indicate the number of unique variants in each consequence category and orange bars indicate the corresponding percentage of all unique variants identified in this review (total = 48). Frameshift variants were most frequent (17/48, 36%), followed by missense (14/48, 29%) and nonsense (7/48, 15%) variants. Splice-site variants accounted for 6% (splice donor, 3/48) and 4% (splice acceptor, 2/48). Intronic and synonymous (“silent”) variants each accounted for 2% (1/48). For 3/48 variants (6%), the molecular consequence was not reported in the source publication (Not reported). Abbreviation: DYSF: Dysferlin.

The clinical classification of the various mutations shows a predominance of pathogenic mutations (72%), followed by likely pathogenic mutations (8%) and variants of uncertain significance (6%). Fourteen percent of the mutations lacked any reported clinical classification (Figure 6). The initial classification source was based on articles reporting the mutations, supplemented by research in the LOVD and ClinVar.

Figure 6.
Figure 6. Distribution of reported DYSF variants by clinical classification. Bars show the number (left) and percentage (right) of unique DYSF variants assigned to each clinical classification category (total = 48). Most variants were classified as pathogenic (35/48, 72%), followed by likely pathogenic (4/48, 8%) and variants of uncertain significance (3/48, 6%). For 7/48 variants (14%), a clinical classification was not reported in the source publication and no curated classification was identified during database cross-checking (Not reported). Classifications were extracted primarily from the original reports and, when necessary, supplemented by evidence from LOVD and ClinVar. Abbreviations: DYSF: Dysferlin; LOVD: Leiden Open Variation Database; VUS: Variant of uncertain significance.

The distribution of variants from the 48 analyzed mutations across the two databases is as follows: 21 (44%) were identified in both LOVD and ClinVar, 12 (25%) variants were not found in either database, 9 (19%) variants were found in LOVD only, and 6 (12%) in ClinVar only. The query dates used for these counts were January 7, 2026 (Figure 7).

Figure 7.
Figure 7. Presence of reported DYSF variants in curated variant databases (LOVD and ClinVar). Horizontal bars show the number (blue) and percentage (orange) of unique DYSF variants identified in this review (total = 48) that were present in both databases (Both), in only one database (LOVD only or ClinVar only), or in neither database (Neither). Twenty-one variants (21/48, 44%) were found in both LOVD and ClinVar, 9/48 (19%) were found in LOVD only, 6/48 (12%) were found in ClinVar only, and 12/48 (25%) were not identified in either database at the time of querying. Database searches were performed on 7 January 2026. Abbreviations: DYSF: Dysferlin; LOVD: Leiden Open Variation Database.

Study quality evaluation

As detailed in Table S2 and Table S3, the methodological quality of the included studies was assessed using the JBI Critical Appraisal Checklist. Although some concerns were noted based on the JBI appraisal, all articles were ultimately retained. Overall, the methodological quality of the included case series was moderate. Most studies clearly defined inclusion criteria and employed reliable diagnostic methods. However, the consecutive and complete inclusion of participants was often unclear, and follow-up information was inconsistently reported. These limitations are characteristic of descriptive case series, particularly in the context of rare diseases. The four included case reports demonstrated adequate methodological quality, featuring clear patient descriptions, reliable diagnostic methods, and well-documented clinical presentations. Some limitations were noted, particularly regarding follow-up information and the reporting of additional clinical details, which were not always applicable or fully addressed. Nevertheless, the included studies provide valuable clinical and genetic information that is essential for qualitative synthesis.

Discussion

Dysferlinopathy constitutes a heterogeneous group of clinical disorders primarily characterized by two clinical presentations: LGMDR2, which manifests as proximal lower limb muscle weakness, and myopathy, characterized by distal muscle weakness in the lower limbs [49]. Although these two entities are now unified under the classification of dysferlinopathies [24], the literature often discusses them separately. The prevalence of dysferlinopathies is estimated to range from 1 in 14,000 to 1 in 2 million, making them one of the most common forms of LGMD [50].

A study conducted by Rochdi et al. identified the most frequently altered genes associated with myopathies in the Middle East and North Africa (MENA) population, specifically the DYSF, SGCG, and LAMA2 genes [51]. In the studies included in this review, 48 unique DYSF variants were reported across Arab populations, with the LGMDR2 phenotype being the most frequently assigned (26 out of 52 cases). In Tunisia, Laroussi et al. reported that among 20 patients, the most common phenotypes were LGMDR2 and PD LGMD, each accounting for 35% of cases [52]. In contrast, a study in Saudi Arabia involving 53 subjects from 33 families found the LGMDR2 phenotype in 30.19%, the MM phenotype in 50.94%, and the PD phenotype in 15.09% [31].

The research by Alharbi et al. in Saudi Arabia identified 13 different mutations in patients from 29 unrelated families, with the c.164_165insA mutation being the most prevalent, affecting 28 patients from 19 unrelated families. The c.1433delC mutation was the second most frequent, observed in three patients from two unrelated families [31]. In Tunisia, five distinct mutations were reported among 21 patients from unrelated families, with the c.3113G>A (p.Arg1038Gln) mutation identified in nine patients, followed by c.4597-2A>G in three patients [29, 39]. In the Libyan Jewish community, 29 patients were found to carry the c.4872delG (p.Glu1624Aspfs*10) founder mutation [30].

Nguyen et al. reported three mutations in the DYSF gene among Moroccan patients: c.2858dupT (p.Phe954Valfs2), c.5594delG (p.Gly1865Alafs101), and c.4200delC (p.Ile1401Serfs*47) [38, 47]. In our Medical Genetics Laboratory at the Mohammed VI University Hospital Center of Oujda, the c.5594delG mutation was confirmed in a patient with dysferlinopathy, whose brother and two cousins also exhibited similar clinical features. This mutation has been identified in the two cousins (data not published; the Biomedical Research Ethics Committee of Oujda, Morocco (CERBO), approved the ethical protocol for this study). At the complementary DNA level, the c.5594delG mutation represents a deletion of guanine (G) at position 5594 in exon 50 of the DYSF gene. At the protein level, it results in the substitution of glycine for alanine at codon 1865, leading to a frameshift and premature termination of protein production after an additional 101 amino acids. This mutation has also been documented in Spanish and Belgian families. The recurrent frameshift mutation c.5594delG is not associated with a specific ethnic group or phenotype [47].

This review suggests that the c.5594delG mutation may represent a recurrent variant observed in multiple unrelated Moroccan patients. Further investigation through larger Moroccan cohorts or founder analyses in patients exhibiting clinical features suggestive of dysferlinopathy is warranted.

The Moroccan Genetic Disease Database (MGDD) does not currently include the c.4200delC (p.Ile1401Serfs*47) mutation, which should be added to facilitate ongoing research. The other two mutations have been included in the database [53].

The geographical distribution of mutations reported in the literature is influenced by demographic factors, including population size, consanguinity, access to molecular diagnostic techniques, and potential publication bias.

Demographically, Egypt has the largest population, estimated at around 116.5 million inhabitants in 2024, followed by Algeria, Morocco, and Saudi Arabia. This demographic distribution significantly influences the total number of reported cases (Table 2) [54, 55].

Table 2 Consanguinity and demographic profiles of Arab countries
Countries Overall consanguinty rate % Population mid-2024 (millions)
Egypt 20.9–80.4 [32] 116.5 [55]
Algeria 22.6–34 [32] 46.8 [55]
Saudi Arabia 42.1–66.7 [32] 34.0 [55]
Morocco 19.9–28 [32] 38.1 [55]
Tunisia 20.1–39.3 [32] 12.3 [55]
Libya 48.4 [32] 7.4 [55]

The high prevalence of certain autosomal recessive diseases, such as dystrophinopathies, within Arab populations can be partially attributed to the elevated rates of consanguineous marriages. This phenomenon is particularly documented in Saudi Arabia and Egypt, where consanguinity rates are among the highest globally (Table 2) [32, 33, 56].

While some countries have established national genomics projects and specialized centers (Saudi Arabia, Qatar, Egypt, and the United Arab Emirates), such initiatives are not yet widespread across all Arab nations [57].

In a cohort analysis of 134 patients with dysferlinopathy from various countries, Krahn et al. demonstrated the following distribution of mutation types: 28% frameshift mutations, 26% missense mutations, 26% nonsense mutations, 18% intronic mutations, and 1% in-frame deletions [58]. The study by Blandin et al. reported a total of 266 different types of mutations, categorized as follows: 27.8% frameshift mutations, 33.1% missense mutations, 18.0% nonsense mutations, and 3.8% in-frame exonic insertions or deletions [26]. In Nguyen et al.’s study of 34 patients with dysferlinopathy, the identified mutations included 17 missense mutations, 13 frameshift mutations, 13 nonsense mutations, 7 substitutions or small deletions at splice sites, 1 intronic one-base-pair substitution, and 3 in-frame insertions [47]. The mutations identified in our review include 36% frameshift mutations, 29% missense mutations, 15% nonsense mutations, 6% splice donor mutations, and 4% splice acceptor mutations, with intronic and silent mutations each representing 2%. Notably, the most prevalent types of disease-causing mutations are frameshift, missense, and nonsense mutations.

Several studies have indicated that there is no correlation between genotype and phenotype in dysferlinopathies. Even within families, identical mutations can lead to divergent phenotypes [50, 59, 60]. Moreover, in Arab populations, identified mutations are dispersed throughout the entire coding sequence of the DYSF gene, with no identifiable ‘hotspot’ mutations. Genotype alone is insufficient for predicting disease outcomes, as the same homozygous mutation can present with variable clinical manifestations. This suggests that factors beyond genetics, including environmental influences, may also modulate phenotypic expression [31, 58].

In the study by Rekik et al., a Tunisian family was identified with three members affected by dysferlinopathy, all sharing the same mutation, c.4597-2A>G, in the DYSF gene. This mutation resulted in the deletion of 28 bp from exon 43, leading to an intra-familial variety of dysferlinopathies, including the PD phenotype, LGMDR2, and DMAT [29, 39]. Similarly, Belhassen et al. reported that nine patients from three different families in Tunisia shared the homozygous missense mutation c.3113G>A, yet exhibited diverse phenotypes (LGMDR2, HyperCKemia, and PD). Additionally, the reading frameshift mutation c.4200dupC, found in two families, was associated with various phenotypes, including LGMDR2, MM, and HyperCKemia [29]. The c.5594delG mutation has also been linked to different phenotypes: PD in a Moroccan patient and Miyoshi myopathy in a Belgian patient [47].

In our dataset, the c.5594delG variant was identified in a single Moroccan family. While this variant has been documented in Moroccan patients in the literature, it has not yet been described in a Morocco-based cohort study; thus, the available evidence regarding Moroccan cases remains limited to isolated reports.

Compound heterozygous gene mutations refer to the presence of two or more heterogeneous recessive alleles at a specific locus, resulting in a genetic disease in the heterozygous state [31]. Our review identified six distinct compound heterozygous mutations. Two mutations, c.1834C>T/c.3967C>T and c.1834C>T/c.4876delG, were reported from Algeria, with one associated with the LGMDR2 phenotype and the other with the PD phenotype [38]. Two mutations from Saudi Arabia, c.1422C>T/c.359A>C and a triple heterozygous mutation c.1351A>G/c.5264T>C/c.3702+6T>A, both resulted in the LGMDR2 phenotype [31]. Additionally, two mutations, c.2190dupA/c.3597G>A and c.4101G>A/c.6124C>T, were reported in Egypt [45].

The LOVD, established in 1998 for dysferlin, serves as the only locus-specific database providing public reference for human dysferlin variants [26]. Our review revealed that 12 mutations were not documented in either the LOVD or ClinVar databases. These findings are significant as they indicate the limited global recognition of Arab mutations, underscoring the necessity to strengthen efforts in collecting and incorporating Arab mutations into these databases to enhance diagnosis and research. Consequently, creating comprehensive databases that encompass the various mutations found in Arab populations and ensuring their regular updates is essential.

Limitations

This study has several limitations that should be considered when interpreting the results.

A comprehensive investigation is needed to establish a clearer understanding of the mutational profile of the DYSF gene in Morocco. This should involve collaboration with various genetic diagnostic centers throughout Morocco to gather comprehensive data on patients with dysferlinopathy.

Most of the included studies were conducted on small, heterogeneous samples.

There are potential biases related to selection and publication, as the patients included in studies may not represent the general population, and many studies tend to report positive mutation findings predominantly.

Finally, due to the limited number of studies and small sample sizes, a meta-analytic approach to data synthesis was not feasible, leading to a diminished quantitative synthesis.

Conclusion

This review summarizes the mutations documented in eight Arab countries, reporting a total of 48 different variants of the DYSF gene, primarily consisting of frameshift and nonsense mutations. No mutational hotspots were identified.

To date, no Morocco-based cohort study on genetic dysferlinopathy has been published, though this study has reported an isolated Moroccan case. This highlights the urgent need for an Arab dysferlinopathy registry and inclusion in the LOVD/ClinVar databases.

Accurate characterization of the DYSF mutational spectrum is crucial for refining diagnostic strategies.

The observed differences in the number of patients with the DYSF gene mutations across various countries may be attributed to technological advancements in some regions compared to others, founder effects, patterns of consanguinity, registry activities, and practices surrounding referral and publication.

The absence of reported DYSF gene mutations in some countries likely reflects underdiagnosis, underreporting, and unequal access to sequencing, rather than a genuine absence of mutations or disease. Thus, this review offers a snapshot of published variants and should not be used to infer the prevalence or incidence of the disease.

Supplemental data

Supplemental data are available at the following link: https://www.bjbms.org/ojs/index.php/bjbms/article/view/13439/4130.

References

  1. Pramono ZAD, Tan CL, Seah IAL, See JSL, Kam SY, Lai PS, et al. Identification and characterisation of human dysferlin transcript variants: Implications for dysferlin mutational screening and isoforms. Hum Genet 2009;125(4):413–20. https://doi.org/10.1007/s00439-009-0632-y
  2. Poudel BH, Fletcher S, Wilton SD, Aung-Htut M. Limb girdle muscular dystrophy type 2B (LGMD2B): diagnosis and therapeutic possibilities. Int J Mol Sci 2024;25(11):5572. https://doi.org/10.3390/ijms25115572
  3. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdlemuscular dystrophy. Nat Genet 1998;20(1):31–6. https://doi.org/10.1038/1682
  4. Rougier JS, Abriel H. Cardiac voltage-gated calcium channel macromolecular complexes. Biochim Biophys Acta Mol Cell Res 2016;1863(7):1806–12. https://doi.org/10.1016/j.bbamcr.2015.12.014
  5. Wang N, Han X, Hao S, Han J, Zhou X, Sun S, et al. The clinical, myopathological, and molecular characteristics of 26 Chinese patients with dysferlinopathy: a high proportion of misdiagnosis and novel variants. BMC Neurol 2022;22(1):398. https://doi.org/10.1186/s12883-022-02905-w
  6. Furrer R, Dilbaz S, Steurer SA, Santos G, Karrer-Cardel B, Ritz D, et al. Metabolic dysregulation contributes to the development of dysfer-linopathy. Life Sci Alliance 2025;8(5):e202402991. https://doi.org/10.26508/lsa.202402991
  7. Anderson LVB, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999;8(5):855–61. https://doi.org/10.1093/hmg/8.5.855
  8. Paulke NJ, Fleischhacker C, Wegener JB, Riedemann GC, Cretu C, Mushtaq M, et al. Dysferlin enables tubular membrane proliferation in cardiac hypertrophy. Circ Res 2024;135(5):554–74. https://doi.org/10.1161/CIRCRESAHA.124.324588
  9. Jin SQ, Yu M, Zhang W, Lyu H, Yuan Y, Wang ZX. Dysferlin gene mutation spectrum in a large cohort of Chinese patients with dysfer- linopathy. Chin Med J 2016;129(19):2287–93. https://doi.org/10.4103/0366-6999.190671
  10. Escobar H, Di Francescantonio S, Smirnova J, Graf R, Müthel S, Marg A, et al. Gene-editing in patient and humanized-mice primary muscle stem cells rescues dysferlin expression in dysferlin-deficient muscu-lar dystrophy. Nat Commun 2025;16(1):120. https://doi.org/10.1038/s41467-024-55086-0
  11. Bouchard C, Tremblay JP. Portrait of dysferlinopathy: diagnosis and development of therapy. J Clin Med 2023;12(18):6011. https://doi.org/10.3390/jcm12186011
  12. Cárdenas AM, González-Jamett AM, Cea LA, Bevilacqua JA, Caviedes P. Dysferlin function in skeletal muscle: possible pathological mechanisms and therapeutical targets in dysferlinopathies. Exp Neurol 2016;283:246–54. https://doi.org/10.1016/j.expneurol.2016.06.026
  13. Quinn CJ, Cartwright EJ, Trafford AW, Dibb KM. On the role of dysfer-lin in striated muscle: membrane repair, t-tubules and Ca2+ handling. J Physiol 2024;602(9):1893–910. https://doi.org/10.1113/JP285103
  14. Cenacchi G, Fanin M, De Giorgi LB, Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mech-anism. J Clin Pathol 2005;58(2):190–5. https://doi.org/10.1136/jcp.2004.018978
  15. Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998;20(1):37–42. https://doi.org/10.1038/1689
  16. Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol 2004;14(4):206–13. https://doi. org/10.1016/j.tcb.2004.03.001
  17. Krajacic P, Hermanowski J, Lozynska O, Khurana TS, Lamitina T. C. elegans dysferlin homolog fer-1 is expressed in muscle, and fer-1 mutations initiate altered gene expression of muscle enriched genes. Physiol Genomics 2009;40(1):8–14. https://doi.org/10.1152/physiolgenomics.00106.2009
  18. Britton S, Freeman T, Vafiadaki E, Keers S, Harrison R, Bushby K, et al. The third human FER-1-like protein is highly similar to dysfer-lin. Genomics 2000;68(3):313–21. https://doi.org/10.1006/geno.2000.6290
  19. Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers SM, et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001;57(2):271–8. https://doi.org/10.1212/WNL.57.2.271
  20. Chen YL, Wu WB, Wang P, Yip PK, Wu YN, Lin YH, et al. Novel five nucleotide deletion in dysferlin leads to autosomal recessive limb-girdle muscular dystrophy. Physiol Rep 2023;11(24):e15887. https://doi.org/10.14814/phy2.15887
  21. Spadafora P, Qualtieri A, Cavalcanti F, Di Palma G, Gallo O, De Benedittis S, et al. A novel homozygous variant in DYSF gene is associated with autosomal recessive limb-girdle muscular dystrophy R2/2B. Int J Mol Sci 2022;23(16):8932. https://doi.org/10.3390/ijms23168932
  22. Li H, Wang L, Zhang C. A rare case of dysferlinopathy with paternal isodisomy for chromosome 2 determined by exome sequencing. Mol Genet Genomic Med 2023;11(2):e2110. https://doi.org/10.1002/mgg3.2110
  23. Aguirre AS, Romero VI. Clinical description of a homozygous Lys 1169* variant in the DYSF gene associated with autosomal recessive Miyoshi muscular dystrophy type 1:a familial case report. Heliyon 2024;10(15):e35333. https://doi.org/10.1016/j.heliyon.2024.e35333
  24. Moore U, Gordish H, Diaz-Manera J, James MK, Mayhew AG, Guglieri M, et al. Miyoshi myopathy and limb girdle muscular dystro-phy R2 are the same disease. Neuromuscul Disord 2021;31(4):265–80. https://doi.org/10.1016/j.nmd.2021.01.009
  25. Charnay T, Blanck V, Cerino M, Bartoli M, Riccardi F, Bonello-Palot N, et al. Retrospective analysis and reclassification of DYSF variants in a large French series of dysferlinopathy patients. Genet Med 2021;23(8):1574–7. https://doi.org/10.1038/s41436-021-01164-3
  26. Blandin G, Béroud C, Labelle V, Nguyen K, Wein N, Hamroun D, et al. UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene. Hum Mutat 2012;33(3):E2317–31. https://doi.org/10.1002/humu.22015
  27. Weiler T, Bashir R, Anderson LVB, Davison K, Moss JA, Britton S, et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 1999;8(5):871–7. https://doi.org/10.1093/hmg/8.5.871
  28. Fanin M, Angelini C. Progress and challenges in diagnosis of dysfer-linopathy. Muscle Nerve 2016;54(5):821–35. https://doi.org/10.1002/mus.25367
  29. Belhassen I, Laroussi S, Sakka S, Rekik S, Lahkim L, Dammak M, et al. Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile. Neuromuscul Disord 2023;33(10):718–27. https://doi.org/10.1016/j.nmd.2023.08.007
  30. Argov Z, Sadeh M, Mazor K, Soffer D, Kahana E, Eisenberg I, et al. Muscular dystrophy dueto dysferlin deficiency in Libyan Jews: clinical and geneticfeatures. Brain 2000;123(Pt 6):1229–37. https://doi.org/10.1093/brain/123.6.1229
  31. Alharbi N, Matar R, Cupler E, Al-Hindi H, Murad H, Alhomud I, et al. Clinical, neurophysiological, radiological, pathological, and genetic features of dysferlinopathy in Saudi Arabia. Front Neurosci 2022;16:815556. https://doi.org/10.3389/fnins.2022.815556
  32. Al-Gazali L, Hamamy H. Consanguinity and dysmorphology in Arabs. Hum Hered 2014;77(1–4):93–107. https://doi.org/10.1159/000360421
  33. Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health 2009;6(1):1–9. https://doi.org/10.1186/1742-4755-6-17
  34. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71
  35. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 2020;18(10):2127–33. https://doi.org/10.11124/JBISRIR-D-19-00099
  36. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE Guidelines: consensus-based clinical case reporting guide- line development. Headache 2013;53(10):1541–7. https://doi.org/10.1111/head.12246
  37. Sanicola K, Shadani N, Nemec EC 2nd, Rose SJ. Myocarditis and pericarditis in young patients following Campylobacter jejuni enterocolitis infection: a systematic review of case studies. J Med Case Rep 2024;18(1):566. https://doi.org/10.1186/s13256-024-04921-5
  38. Nguyen K, Bassez G, Krahn M, Bernard R, Laforêt P, Labelle V, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64(8):1176–82. https://doi.org/10.1001/archneur.64.8.1176
  39. Rekik S, Sakka S, Ben Romdhane S, Ben Amer Y, Lehkim L, Farhat N, et al. Novel splicing dysferlin mutation causing myopathy with intra-familial heterogeneity. Mol Biol Rep 2020;47(8):5755–61. https://doi.org/10.1007/s11033-020-05643-9
  40. Nouioua S, Cherallah A, Benahmed M, Mathieu C, Krahn M, Hamadouche T, et al. Description d’une famille algérienne associant une dysferlinopathie et une merosinopathie primaires. Rev Neurol 2017;173:S68–9. https://doi.org/10.1016/j.neurol.2017.01.082
  41. Aldosari KH, Al-Ghamdi S, Alkhathlan KM, Alkhalidi HM. Phenotypic and genotypic analysis of limb-girdle muscular dystrophy type 2B. Neurosciences 2020;25(3):214–7. https://doi.org/10.17712/nsj.2020.3.20200002
  42. Algahtani H, Shirah B, Alassiri AH, Habib BA, Almuhanna R, Ahamed MF. Limb-girdle muscular dystrophy type 2B: an unusual cause of proximal muscular weakness in Saudi Arabia. J Back Musculoskelet Rehabil 2018;31(5):999–1004. https://doi.org/10.3233/BMR-181129
  43. Pratibha N.. Centre for Arab Genomic Studies. 2020. Available. from: https://cags.org.ae/en/ctga-details/575/dysferlin?keyword=Dysferlin
  44. Megarbane A, Bizzari S, Deepthi A, Sabbagh S, Mansour H, Chouery E, et al. A 20-year clinical and genetic neuromuscular cohort analysis in Lebanon: an international effort. J Neuromuscul Dis 2022;9(1):193–210. https://doi.org/10.3233/JND-210652
  45. El Sherif R, Hussein RS, Nishino I. “Boule du biceps” in dysfer-linopathy. Neurology 2020;94(2):83–4. https://doi.org/10.1212/WNL.0000000000008782
  46. Okubo M, Iida A, Hayashi S, Mori-Yoshimura M, Oya Y, Watanabe A, et al. Three novel recessive DYSF mutations identified in three patients with muscular dystrophy, limb-girdle, type 2B. J Neurol Sci 2018;395:169–71. https://doi.org/10.1016/j.jns.2018.10.015
  47. Nguyen K, Bassez G, Bernard R, Krahn M, Labelle V, Figarella-Branger D,, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. HumMutat 2005;26(2):165. https://doi.org/10.1002/humu.9355
  48. Rajab A, Hamza N, Al Harasi S, Al Lawati F, Gibbons U, Al Alawi I, et al. Repository of mutations from Oman: the entry point to a national mutation database. F1000Res 2015;4:891. https://doi.org/10.12688/f1000research.6938.1
  49. Mahjneh I, Marconi G, Bushby K, Anderson LVB, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord 2001;11(1):20–6. https://doi.org/10.1016/S0960-8966(00)00157-7
  50. Anwar S, Yokota T. The dysferlinopathies conundrum: clinical spec-tra, disease mechanism and genetic approaches for treatments. Biomolecules 2024;14(3):256. https://doi.org/10.3390/biom14030256
  51. Rochdi K, Barakat A, Saile R. Inherited myopathies in the Middle East and North Africa. Gene Rep 2022;29:101674. https://doi.org/10.1016/j.genrep.2022.101674
  52. Laroussi S, Sakka S, Belhassen I, Moalla KS, Daoud S, Dammak M, et al. Dysferlinopathie: caractéristiques cliniques et profil évolu- tif. Rev Neurol 2023;179(Dm):S112–3. https://doi.org/10.1016/j.neurol.2023.01.590
  53. Charoute H, Nahili H, Abidi O, Gabi K, Rouba H, Fakiri M, et al. The Moroccan Genetic Disease Database (MGDD): a database for DNA variations related to inherited disorders and disease susceptibility. Eur J Hum Genet 2014;22(3):322–6. https://doi.org/10.1038/ejhg.2013.151
  54. Daw MA, El-Bouzedi AH, Abumahara SA, Najjar AK, Ben Ashur NR, Grebi A, et al. Geographic mapping and spatiotemporal patterns of tuberculosis in Libya within ten years’ period (2015 to 2024). Front Epidemiol 2025;5:1571065. https://doi.org/10.3389/fepid.2025.1571065
  55. Pison G, Poniakina S. The population of the world (2024). Popul Soc. 2024;626(9):1–8. https://doi.org/10.3917/popsoc.626.0001
  56. El-hazmi MAF, Warsy AS, Sulaimani R. Consanguinity in the Saudi Arabian population. J Med Genet 1995;32(8):623–6. https://doi.org/10.1136/jmg.32.8.623
  57. Ateia H, Ogrodzki P, Wilson HV, Ganesan S, Halwani R, Koshy A, et al. Population genome programs across the Middle East and North Africa: successes, challenges, and future directions. Biomed Hub 2023;8(1):60–71. https://doi.org/10.1159/000530619
  58. Krahn M, Béroud C, Labelle V, Nguyen K, Bernard R, Bassez G, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2009;30(2):E345–75. https://doi.org/10.1002/humu.20910
  59. Ueyama H, Kumamoto T, Horinouchi H, Fujimoto S, Aono H, Tsuda T. Clinical heterogeneity in dysferlinopathy. Intern Med 2002;41(7):532–6. https://doi.org/10.2169/internalmedicine.41.532
  60. Umakhanova ZR, Bardakov SN, Mavlikeev MO, Chernova ON, Magomedova RM, Akhmedova PG, et al. Twenty-year clinical progression of dysferlinopathy in patients from Dagestan. Front Neurol 2017;8:77. https://doi.org/10.3389/fneur.2017.00077

About this article

Correspondence

*Correspondence to Fatimazahra Smaili: [email protected]

Article history

Received: 2025-10-25 · Rev-recd: 2026-02-12 · Accepted: 2026-02-03

Conflicts of interest

Conflicts of interest: Authors declare no conflicts of interest.

Funding

Funding: Authors received no specific funding for this work.

Copyright

© 2026 Smaili et al.

Downloads

Download data is not yet available.

References

Pramono ZAD, Tan CL, Seah IAL, See JSL, Kam SY, Lai PS, et al. Identification and characterisation of human dysferlin transcript variants: Implications for dysferlin mutational screening and isoforms. Hum Genet 2009;125(4):413–20. https://doi.org/10.1007/ DOI: https://doi.org/10.1007/s00439-009-0632-y

s00439-009-0632-y

Poudel BH, Fletcher S, Wilton SD, Aung-Htut M. Limb girdle muscular dystrophy type 2B (LGMD2B): diagnosis and therapeutic possibilities. Int J Mol Sci 2024;25(11):5572. https://doi.org/10.3390/ijms25115572 DOI: https://doi.org/10.3390/ijms25115572

Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdlemuscular dystrophy.Nat Genet 1998;20(1):31–6.https://doi.org/10.1038/1682 DOI: https://doi.org/10.1038/1682

Rougier JS, Abriel H. Cardiac voltage-gated calcium channel macromolecular complexes. Biochim Biophys Acta Mol Cell Res

;1863(7):1806–12. https://doi.org/10.1016/j.bbamcr.2015.12.014 DOI: https://doi.org/10.1016/j.bbamcr.2015.12.014

Wang N, Han X, Hao S, Han J, Zhou X, Sun S, et al. The clinical, myopathological, and molecular characteristics of 26 Chinese patients with dysferlinopathy: a high proportion of misdiagnosis and novel variants. BMC Neurol 2022;22(1):398. https://doi.org/10.1186/s12883-022-02905-w DOI: https://doi.org/10.1186/s12883-022-02905-w

Furrer R, Dilbaz S, Steurer SA, Santos G, Karrer-Cardel B, Ritz D, et al. Metabolic dysregulation contributes to the development of dysferlinopathy. Life Sci Alliance 2025;8(5):e202402991. https://doi.org/10. DOI: https://doi.org/10.26508/lsa.202402991

/lsa.202402991

Anderson LVB, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999;8(5):855–61. https://doi.org/10.1093/hmg/8.5.855 DOI: https://doi.org/10.1093/hmg/8.5.855

Paulke NJ, Fleischhacker C, Wegener JB, Riedemann GC, Cretu C, Mushtaq M, et al. Dysferlin enables tubular membrane proliferation in cardiac hypertrophy. Circ Res 2024;135(5):554–74. https://doi.org/10.1161/CIRCRESAHA.124.324588 DOI: https://doi.org/10.1161/CIRCRESAHA.124.324588

Jin SQ, Yu M, Zhang W, Lyu H, Yuan Y, Wang ZX. Dysferlin gene mutation spectrum in a large cohort of Chinese patients with dysferlinopathy. Chin Med J 2016;129(19):2287–93. https://doi.org/10.4103/0366-6999.190671 DOI: https://doi.org/10.4103/0366-6999.190671

EscobarH, Di Francescantonio S, Smirnova J, Graf R,Müthel S,Marg A, et al. Gene-editing in patient and humanized-mice primary muscle stem cells rescues dysferlin expression in dysferlin-deficient muscular dystrophy. Nat Commun 2025;16(1):120. https://doi.org/10.1038/s41467-024-55086-0 DOI: https://doi.org/10.1038/s41467-024-55086-0

Bouchard C, Tremblay JP. Portrait of dysferlinopathy: diagnosis and development of therapy. J Clin Med 2023;12(18):6011. https://doi.org/10.3390/jcm12186011 DOI: https://doi.org/10.3390/jcm12186011

Cárdenas AM, González-Jamett AM, Cea LA, Bevilacqua JA, Caviedes P. Dysferlin function in skeletal muscle: possible pathological mechanisms and therapeutical targets in dysferlinopathies. Exp Neurol 2016;283:246–54. https://doi.org/10.1016/j.expneurol.2016.06.026 DOI: https://doi.org/10.1016/j.expneurol.2016.06.026

Quinn CJ, Cartwright EJ, Trafford AW, Dibb KM. On the role of dysferlin in striated muscle: membrane repair, t-tubules and Ca2+ handling. J Physiol 2024;602(9):1893–910. https://doi.org/10.1113/JP285103 DOI: https://doi.org/10.1113/JP285103

Cenacchi G, Fanin M, De Giorgi LB, Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005;58(2):190–5. https://doi.org/10.1136/jcp. 2004.018978 DOI: https://doi.org/10.1136/jcp.2004.018978

Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998;20(1):37–42. https://doi.org/10.1038/1689 DOI: https://doi.org/10.1038/1689

Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol 2004;14(4):206–13. https://doi. org/10.1016/j.tcb.2004.03.001 DOI: https://doi.org/10.1016/j.tcb.2004.03.001

Krajacic P, Hermanowski J, Lozynska O, Khurana TS, Lamitina T. C. elegans dysferlin homolog fer-1 is expressed in muscle, and fer- 1 mutations initiate altered gene expression of muscle enriched genes. Physiol Genomics 2009;40(1):8–14. https://doi.org/10.1152/physiolgenomics.00106.2009 DOI: https://doi.org/10.1152/physiolgenomics.00106.2009

Britton S, Freeman T, Vafiadaki E, Keers S, Harrison R, Bushby K, et al. The third human FER-1-like protein is highly similar to dysferlin. Genomics 2000;68(3):313–21. https://doi.org/10.1006/geno.2000.6290 DOI: https://doi.org/10.1006/geno.2000.6290

Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers SM, et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001;57(2):271–8. https://doi.org/10.1212/WNL.57.2.271 DOI: https://doi.org/10.1212/WNL.57.2.271

Chen YL, Wu WB, Wang P, Yip PK, Wu YN, Lin YH, et al. Novel five nucleotide deletion in dysferlin leads to autosomal recessive limb-girdle muscular dystrophy. Physiol Rep 2023;11(24):e15887. https://doi.org/10.14814/phy2.15887 DOI: https://doi.org/10.14814/phy2.15887

Spadafora P, Qualtieri A, Cavalcanti F, Di Palma G, Gallo O, De Benedittis S, et al. A novel homozygous variant in DYSF gene is associated with autosomal recessive limb-girdle muscular dystrophy R2/2B. Int J Mol Sci 2022;23(16):8932. https://doi.org/10.3390/ijms23168932 DOI: https://doi.org/10.3390/ijms23168932

Li H, Wang L, Zhang C. A rare case of dysferlinopathy with paternal isodisomy for chromosome 2 determined by exome sequencing. Mol Genet Genomic Med 2023;11(2):e2110. https://doi.org/10.1002/mgg3. 2110 DOI: https://doi.org/10.1002/mgg3.2110

Aguirre AS, Romero VI. Clinical description of a homozygous Lys 1169* variant in the DYSF gene associated with autosomal recessive Miyoshi muscular dystrophy type 1:a familial case report. Heliyon 2024;10(15):e35333. https://doi.org/10.1016/j.heliyon.2024.e35333 DOI: https://doi.org/10.1016/j.heliyon.2024.e35333

Moore U, Gordish H, Diaz-Manera J, James MK, Mayhew AG, Guglieri M, et al. Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease. Neuromuscul Disord 2021;31(4):265–80. https://doi.org/10.1016/j.nmd.2021.01.009 DOI: https://doi.org/10.1016/j.nmd.2021.01.009

Charnay T, Blanck V, Cerino M, Bartoli M, Riccardi F, Bonello-Palot N, et al. Retrospective analysis and reclassification of DYSF variants in a large French series of dysferlinopathy patients. Genet Med 2021;23(8):1574–7. https://doi.org/10.1038/s41436-021-01164-3 DOI: https://doi.org/10.1038/s41436-021-01164-3

Blandin G, Béroud C, Labelle V, Nguyen K, Wein N, Hamroun D, et al. UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene. Hum Mutat 2012;33(3):E2317–31. https://doi.org/10.1002/humu.22015 DOI: https://doi.org/10.1002/humu.22015

Weiler T, Bashir R, Anderson LVB, Davison K, Moss JA, Britton S, et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 1999;8(5):871–7. https://doi.org/10.1093/hmg/8.5.871 DOI: https://doi.org/10.1093/hmg/8.5.871

Fanin M, Angelini C. Progress and challenges in diagnosis of dysferlinopathy. Muscle Nerve 2016;54(5):821–35. https://doi.org/10.1002/mus.25367 DOI: https://doi.org/10.1002/mus.25367

Belhassen I, Laroussi S, Sakka S, Rekik S, Lahkim L, Dammak M, et al. Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile. Neuromuscul Disord 2023;33(10):718–27. https://doi.org/10.1016/j.nmd.2023.08.007 DOI: https://doi.org/10.1016/j.nmd.2023.08.007

Argov Z, Sadeh M, Mazor K, Soffer D, Kahana E, Eisenberg I, et al. Muscular dystrophy dueto dysferlin deficiency in Libyan Jews: clinical and geneticfeatures. Brain 2000;123(Pt 6):1229–37.https://doi.org/10.1093/brain/123.6.1229 DOI: https://doi.org/10.1093/brain/123.6.1229

Alharbi N, Matar R, Cupler E, Al-Hindi H, Murad H, Alhomud I, et al. Clinical, neurophysiological, radiological, pathological, and genetic features of dysferlinopathy in Saudi Arabia. Front Neurosci 2022;16:815556. https://doi.org/10.3389/fnins.2022.815556 DOI: https://doi.org/10.3389/fnins.2022.815556

Al-Gazali L, Hamamy H. Consanguinity and dysmorphology in Arabs. Hum Hered 2014;77(1–4):93–107. https://doi.org/10.1159/000360421 DOI: https://doi.org/10.1159/000360421

Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health 2009;6(1):1–9. https://doi.org/10.1186/1742-4755-6-17 DOI: https://doi.org/10.1186/1742-4755-6-17

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71

Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 2020;18(10):2127–33. https://doi.org/10.11124/JBISRIR-D-19-00099 DOI: https://doi.org/10.11124/JBISRIR-D-19-00099

Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE Guidelines: consensus-based clinical case reporting guideline development. Headache 2013;53(10):1541–7. https://doi.org/10.1111/head.12246 DOI: https://doi.org/10.1111/head.12246

Sanicola K, Shadani N, Nemec EC 2nd,Rose SJ. Myocarditis and pericarditis in young patients following Campylobacter jejuni enterocolitis infection: a systematic review of case studies. J Med Case Rep 2024;18(1):566. https://doi.org/10.1186/s13256-024-04921-5 DOI: https://doi.org/10.1186/s13256-024-04921-5

Nguyen K, Bassez G, Krahn M, Bernard R, Laforêt P, Labelle V, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64(8):1176–82. https://doi.org/10.1001/archneur.64.8.1176 DOI: https://doi.org/10.1001/archneur.64.8.1176

Rekik S, Sakka S, Ben Romdhane S, Ben Amer Y, Lehkim L, Farhat N, et al. Novel splicing dysferlin mutation causing myopathy with intra-familial heterogeneity. Mol Biol Rep 2020;47(8):5755–61.https://doi.org/10.1007/s11033-020-05643-9 DOI: https://doi.org/10.1007/s11033-020-05643-9

Nouioua S, Cherallah A, Benahmed M, Mathieu C, Krahn M, Hamadouche T, et al. Description d’une famille algérienne associant une dysferlinopathie et une merosinopathie primaires. Rev Neurol 2017;173:S68–9. https://doi.org/10.1016/j.neurol.2017.01.082 DOI: https://doi.org/10.1016/j.neurol.2017.01.082

Aldosari KH, Al-Ghamdi S, Alkhathlan KM, Alkhalidi HM. Phenotypic and genotypic analysis of limb-girdle muscular dystrophy type 2B. Neurosciences 2020;25(3):214–7. https://doi.org/10.17712/nsj.2020.3.20200002 DOI: https://doi.org/10.17712/nsj.2020.3.20200002

Algahtani H, Shirah B, Alassiri AH, Habib BA, Almuhanna R, Ahamed MF. Limb-girdle muscular dystrophy type 2B: an unusual cause of proximal muscular weakness in Saudi Arabia. J Back Musculoskelet Rehabil 2018;31(5):999–1004. https://doi.org/10.3233/BMR-181129 DOI: https://doi.org/10.3233/BMR-181129

Pratibha N. Centre for Arab Genomic Studies. 2020. Available from: https://cags.org.ae/en/ctga-details/575/dysferlin?keyword=Dysferlin

Megarbane A, Bizzari S, Deepthi A, Sabbagh S, Mansour H, Chouery E, et al. A 20-year clinical and genetic neuromuscular cohort analysis in Lebanon:aninternationaleffort.JNeuromusculDis2022;9(1):193–210. https://doi.org/10.3233/JND-210652 DOI: https://doi.org/10.3233/JND-210652

El Sherif R, Hussein RS, Nishino I. “Boule du biceps” in dysferlinopathy. Neurology 2020;94(2):83–4. https://doi.org/10.1212/WNL.0000000000008782 DOI: https://doi.org/10.1212/WNL.0000000000008782

Okubo M, Iida A, Hayashi S, Mori-Yoshimura M, Oya Y, Watanabe A, et al. Three novel recessive DYSF mutations identified in three patients with muscular dystrophy, limb-girdle, type 2B. J Neurol Sci 2018;395:169–71. https://doi.org/10.1016/j.jns.2018.10.015 DOI: https://doi.org/10.1016/j.jns.2018.10.015

Nguyen K, Bassez G, Bernard R, Krahn M, Labelle V, Figarella-Branger D, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies.HumMutat 2005;26(2):165.

https://doi.org/10.1002/humu.9355 DOI: https://doi.org/10.1002/humu.9355

Rajab A, Hamza N, Al Harasi S, Al Lawati F, Gibbons U, Al Alawi I, et al. Repository of mutations from Oman: the entry point to a national mutation database. F1000Res 2015;4:891. https://doi.org/10.12688/f1000research.6938.1 DOI: https://doi.org/10.12688/f1000research.6938.1

Mahjneh I, Marconi G, Bushby K, Anderson LVB, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord 2001;11(1):20–6. <https://doi.org/10.1016/S0960-8966(00)00157-7 DOI: https://doi.org/10.1016/S0960-8966(00)00157-7

Anwar S, Yokota T. The dysferlinopathies conundrum: clinical spectra, disease mechanism and genetic approaches for treatments. Biomolecules 2024;14(3):256. https://doi.org/10.3390/biom14030256 DOI: https://doi.org/10.3390/biom14030256

Rochdi K, Barakat A, Saile R. Inherited myopathies in the Middle East and North Africa. Gene Rep 2022;29:101674. https://doi.org/10.1016/j.genrep.2022.101674 DOI: https://doi.org/10.1016/j.genrep.2022.101674

Laroussi S, Sakka S, Belhassen I, Moalla KS, Daoud S, Dammak M, et al. Dysferlinopathie: caractéristiques cliniques et profil évolutif. Rev Neurol 2023;179(Dm):S112–3. https://doi.org/10.1016/j.neurol.2023.01.590 DOI: https://doi.org/10.1016/j.neurol.2023.01.590

Charoute H, Nahili H, Abidi O, Gabi K, Rouba H, Fakiri M, et al. The Moroccan Genetic Disease Database (MGDD): a database for DNA variations related to inherited disorders and disease susceptibility. Eur J Hum Genet 2014;22(3):322–6. https://doi.org/10.1038/ejhg.2013.151 DOI: https://doi.org/10.1038/ejhg.2013.151

Daw MA, El-Bouzedi AH, Abumahara SA, Najjar AK, Ben Ashur NR, Grebi A, et al. Geographic mapping and spatiotemporal patterns of tuberculosis in Libya within ten years’ period (2015 to 2024). Front Epidemiol 2025;5:1571065. https://doi.org/10.3389/fepid.2025.1571065 DOI: https://doi.org/10.3389/fepid.2025.1571065

Pison G, Poniakina S. The population of the world (2024). Popul Soc 2024;626(9):1–8. https://doi.org/10.3917/popsoc.626.0001 DOI: https://doi.org/10.3917/popsoc.626.0001

El-hazmi MAF, Warsy AS, Sulaimani R. Consanguinity in the Saudi Arabian population. J Med Genet 1995;32(8):623–6. https://doi.org/10.1136/jmg.32.8.623 DOI: https://doi.org/10.1136/jmg.32.8.623

Ateia H, Ogrodzki P, Wilson HV, Ganesan S, Halwani R, Koshy A, et al. Population genome programs across the Middle East and North Africa: successes, challenges, and future directions. Biomed Hub 2023;8(1):60–71. https://doi.org/10.1159/000530619 DOI: https://doi.org/10.1159/000530619

Krahn M, Béroud C, Labelle V, Nguyen K, Bernard R, Bassez G, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2009;30(2):E345–75. https://doi.org/10.1002/humu.20910 DOI: https://doi.org/10.1002/humu.20910

Ueyama H, Kumamoto T, Horinouchi H, Fujimoto S, Aono H, Tsuda T. Clinical heterogeneity in dysferlinopathy. Intern Med 2002;41(7): 532–6. https://doi.org/10.2169/internalmedicine.41.532 DOI: https://doi.org/10.2169/internalmedicine.41.532

Umakhanova ZR, Bardakov SN, Mavlikeev MO, Chernova ON, Magomedova RM, Akhmedova PG, et al. Twenty-year clinical progression of dysferlinopathy in patients from Dagestan. Front Neurol 2017;8:77. https://doi.org/10.3389/fneur.2017.00077 DOI: https://doi.org/10.3389/fneur.2017.00077

Article files

Additional Files

Publication details

Citation
Vol. 26 No. 9 (2026), pp. 1511–1522
Language
EN
License
CC BY 4.0
Section
Systematic review/Meta analysis

How to cite (Vancouver)

Smaili F, Zerrouki K, Aouni FE, Tajir M. DYSF gene variant spectrum in Arab populations across eight countries: A systematic review. Biomol Biomed. 2026;26(9):1511–1522. https://doi.org/10.17305/bb.2026.13439

Share

Related articles